Physician profile
Robin L Beach
NPI 1316970379
$427,979.11
in general payments reported to CMS, 2019-2025
14 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129K · 2022: $71K · 2023: $72K · 2024: $74K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Honoraria: $51K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $44K · Travel and Lodging: $36K · Food and Beverage: $11K · Consulting Fee: $9,530 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,195.22 |
| Honoraria | $51,071.34 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43,800.15 |
| Travel and Lodging | $35,680.79 |
| Food and Beverage | $10,840.80 |
| Consulting Fee | $9,530.00 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $244,722.59 | 2021-2025 | Egrifta Sv, Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $80,246.25 | 2021-2025 | Mytesi |
| Gilead Sciences, INC. | $55,275.08 | 2021-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $46,743.12 | 2022-2025 | Cabenuva, Dovato, Apretude |
| Janssen Products, Lp | $322.52 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $160.10 | 2023-2025 | Pifeltro, Delstrigo |
| Emd Serono, INC. | $108.54 | 2024 | Serostim |
| Sanofi-Aventis U.S. LLC | $100.21 | 2022 | |
| Biogen, INC. | $96.19 | 2022 | |
| Abbott Laboratories | $89.30 | 2021 | |
| Stryker Corporation | $44.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.22 | 2021-2023 | |
| Janssen Biotech, INC. | $16.74 | 2021 | |
| Abiomed | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.